Christian Schetter

Christian Schetter has over 20 years’ industry experience in life sciences, and is Managing Director of venture capital firm Arix Bioscience. As CEO he built immuno-oncology company Rigontec and lead it to an acquisition by MSD for a total consideration of EUR 464 m. Previously he was President and CEO of Fresenius Biotech and led the successful spin-out from the Neopharm Group to form Neovii Biotech. As SVP of European Operations, he was part of the leadership team which built Coley Pharmaceuticals from inception, a NASDAQ IPO and the acquisition by Pfizer in 2007. Christian has a PhD in Molecular Biology and hold research positions at the Max Planck Institute and the Scripps Research Institute.